石家庄智康弘仁

Zhikang Hongren is a clinical-stage biotechnology company based in Shijiazhuang, China, specializing in the development of innovative peptide therapeutics for metabolic and endocrine disorders. The company's research focuses on multi-receptor agonists, particularly those targeting the GLP-1, GIP, and glucagon receptors, to provide more effective treatments for obesity and type 2 diabetes. Its lead candidate, ZK002, is a long-acting triple agonist that has entered clinical trials, aiming to achieve superior weight loss and metabolic regulation compared to existing therapies. Zhikang Hongren leverages a proprietary peptide engineering platform to optimize the stability and potency of its drug candidates. The company is supported by regional investment funds and is a prominent player in the Hebei province biotech ecosystem. Its pipeline also includes ZK001, a dual agonist targeting GLP-1 and GIP receptors, and other programs for metabolic-associated steatohepatitis (MASH).